Yumanity Therapeutics announces first clinical candidate for the potential treatment of Parkinson’s disease
First-in-Human Trials Planned for the Fourth Quarter of 2019
IND-Enabling Studies to Be Completed Utilizing Evotec INDiGO Platform
CAMBRIDGE, Mass., September 5, 2018 | Yumanity Therapeutics, a company focused on discovering transformative therapies to treat neurodegenerative diseases, today announced its lead clinical candidate, YTX-7739, is entering IND-enabling studies for the treatment of Parkinson’s disease and related disorders. YTX-7739 is a novel therapeutic, focused on a novel target newly identified to play a role in Parkinson’s Disease discovered using Yumanity Therapeutics’ proprietary drug discovery platform. YTX-7739 is expected to enter first-in-human studies by the fourth quarter of 2019.
